Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
9.99
-1.41 (-12.34%)
At close: Aug 8, 2025
Spruce Biosciences Employees
Spruce Biosciences had 21 employees as of December 31, 2024. The number of employees decreased by 8 or -27.59% compared to the previous year.
Employees
21
Change (1Y)
-8
Growth (1Y)
-27.59%
Revenue / Employee
$145,450
Profits / Employee
-$2,772,600
Market Cap
5.62M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21 | -8 | -27.59% |
Dec 31, 2023 | 29 | 2 | 7.41% |
Dec 31, 2022 | 27 | 12 | 80.00% |
Dec 31, 2021 | 15 | -2 | -11.76% |
Dec 31, 2020 | 17 | 2 | 13.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Federal National Mortgage Association | 8,200 |
Federal Home Loan Mortgage | 8,103 |
Central Bancompany | 2,277 |
Jingbo Technology | 154 |
Wilson Bank Holding Company | 596 |
Spruce Biosciences News
- 16 days ago - Spruce Biosciences Announces Reverse Stock Split - Business Wire
- 19 days ago - HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Business Wire
- 3 months ago - Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 4 months ago - Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) - Seeking Alpha
- 4 months ago - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 8 months ago - Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Benzinga
- 8 months ago - Spruce Biosciences to wind down investment for genetic disorder drug - Reuters